title: Regulation of Cell Proliferation by the Guanosine-Adenosine Mechanism: Role of Adenosine Receptors.
abstract: A recent study (American Journal of Physiology-Cell Physiology 304: C406-C421, 2013) suggests that extracellular guanosine increases extracellular adenosine by modifying the disposition of extracellular adenosine ("guanosine-adenosine mechanism") and that the guanosine-adenosine mechanism is not mediated by classical adenosine transport systems (SLC28 and SLC29 families) nor by classical adenosine-metabolizing enzymes. The present investigation had two aims: 1) to test the hypothesis that the "guanosine-adenosine mechanism" affects cell proliferation; and 2) to determine whether the transporters SLC19A1, SLC19A2, SLC19A3 or SLC22A2 (known to carrier guanosine analogues) might be responsible for the guanosine-adenosine mechanism. In the absence of added adenosine, guanosine had little effect on the proliferation of coronary artery vascular smooth muscle cells (vascular conduit cells) or preglomerular vascular smooth muscle cells (vascular resistance cells). However, in the presence of added adenosine (3 or 10 μmol/L), guanosine (10 to 100 μmol/L) decreased proliferation of both cell types, thus resulting in a highly significant (p<0.000001) interaction between guanosine and adenosine on cell proliferation. The guanosine-adenosine interaction on cell proliferation was abolished by 1,3-dipropyl-8-(p-sulfophenyl)xanthine (adenosine receptor antagonist). Guanosine (30 μmol/L) increased extracellular levels of adenosine when adenosine (3 μmol/L) was added to the medium. This effect was not reproduced by high concentrations of methotrexate (100 μmol/L), thiamine (1000 μmol/L), chloroquine (1000 μmol/L) or acyclovir (10,000 μmol/L), archetypal substrates for SLC19A1, SLC19A2, SLC19A3, and SLC22A2, respectively; and guanosine still increased adenosine levels in the presence of these compounds.
  
  
  CONCLUSIONS
  The guanosine-adenosine mechanism affects cell proliferation and is not mediated by SLC19A1, SLC19A2, SLC19A3 or SLC22A2.
authors: Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15219.
authors: Edwin K
authors: EK
authors: Jackson
authors: Delbert G
authors: DG
authors: Gillespie
keywords: SLC19 family; SLC22A2; adenosine; cell proliferation; guanosine
references: Circ J. 2011;75(6):1287-96
references: 21532177
references: Adv Exp Med Biol. 1998;441:97-106
references: 9781317
references: Handb Exp Pharmacol. 2009;(193):161-88
references: 19639282
references: Biochem Cell Biol. 2006 Dec;84(6):844-58
references: 17215872
references: Bull NYU Hosp Jt Dis. 2007;65(3):168-73
references: 17922664
references: Exp Cell Res. 2010 May 1;316(8):1284-8
references: 20153317
references: Hypertension. 1996 Mar;27(3 Pt 2):766-73
references: 8613238
references: Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H391-401
references: 21622827
references: Arthritis Res. 2002;4(4):266-73
references: 12106498
references: Handb Exp Pharmacol. 2009;(193):1-24
references: 19639277
references: Clin Exp Pharmacol Physiol. 2002 Sep;29(9):843-9
references: 12165053
references: Curr Med Chem. 2008;15(9):917-22
references: 18473799
references: Curr Opin Nephrol Hypertens. 1997 Jan;6(1):88-105
references: 9051360
references: Mod Rheumatol. 2010 Apr;20(2):114-22
references: 19949965
references: Am J Cardiol. 1997 Jun 19;79(12A):11-4
references: 9223357
references: Curr Opin Pulm Med. 2006 Jan;12(1):54-9
references: 16357580
references: J Pharmacol Exp Ther. 2011 May;337(2):444-50
references: 21270135
references: J Pharmacol Exp Ther. 1999 Oct;291(1):76-80
references: 10490889
references: J Pharmacol Exp Ther. 1998 Oct;287(1):223-31
references: 9765341
references: Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C406-21
references: 23242185
references: Biochem Pharmacol. 2009 Apr 1;77(7):1117-24
references: 19041853
references: PLoS One. 2011 Apr 14;6(4):e18704
references: 21533188
references: Curr Top Med Chem. 2010;10(9):860-77
references: 20370662
references: Antioxid Redox Signal. 2011 Oct 15;15(8):2221-34
references: 21126189
references: Anesthesiology. 2009 Oct;111(4):904-15
references: 19741501
references: Hypertension. 2010 Jul;56(1):151-8
references: 20516392
references: Hypertension. 1996 Mar;27(3 Pt 2):786-93
references: 8613241
references: Eur J Pharmacol. 2009 Aug 15;616(1-3):7-15
references: 19464286
references: Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):821-4
references: 18600546
references: Bioorg Med Chem. 2003 Dec 1;11(24):5417-25
references: 14642586
references: Am J Physiol Cell Physiol. 2006 Aug;291(2):C254-65
references: 16571869
references: Pharmacol Ther. 2006 Nov;112(2):358-404
references: 16784779
references: J Clin Invest. 2012 Feb;122(2):693-710
references: 22269324
references: Physiol Rev. 2006 Jul;86(3):901-40
references: 16816141
references: Drug Metab Dispos. 2012 Mar;40(3):617-24
references: 22190696
references: Pflugers Arch. 2004 Feb;447(5):641-6
references: 14770311
references: Ann N Y Acad Sci. 1990;604:130-5
references: 2221704
references: Handb Exp Pharmacol. 2009;(193):471-534
references: 19639292
references: Handb Exp Pharmacol. 2009;(193):383-97
references: 19639289
references: Adv Pharmacol. 2011;61:77-94
references: 21586356
references: Hypertension. 1998 Jan;31(1 Pt 2):516-21
references: 9453355
references: Basic Res Cardiol. 1991;86 Suppl 1:3-11
references: 2036094
references: J Neurochem. 2012 May;121(3):329-42
references: 22335456